Concurrent Prostatic Adenocarcinoma and Lymphoma: Clinicopathologic Study of 10 Cases

Abstract

Abstract Introduction/Objective Synchronous and meta-synchronous hematolymphoid neoplasms and prostatic adenocarcinomas are known to occur, albeit rarely. The purpose of this study is to identify the clinicopathologic features of patients with coexisting prostatic adenocarcinoma and a lymphoma diagnosis. Methods/Case Report The institutional pathology archive was searched from 2016 to 2021. Data such as patient age, Gleason score, pathologic tumor stage, type of lymphoma and follow up data were collected. Results (if a Case Study enter NA) Ten patients were identified. Mean patient age was 65.4 ± 5.7 years. Nine specimens were prostatectomies and 1 was a needle core biopsy. Four patients had previous lymphoma diagnoses while 6 were diagnosed with lymphoma on lymph node dissection for prostatectomies. Seven patients had Gleason grade 3 + 4=7 disease, two had Gleason grade 4 + 3=7 and one had Gleason grade 4 + 5=9. Seven patients had small lymphocytic lymphoma/chronic lymphocytic leukemia, one had follicular lymphoma, one had mantle cell lymphoma and one had peripheral T-cell lymphoma. The patient with peripheral T-cell lymphoma died 18 months after lymphoma diagnosis and 11 months after prostate cancer diagnosis. The remaining 9 patients were alive for a mean of 27.7 ± 22.6 months after prostate cancer diagnosis. Conclusion There is minimal literature on patients with synchronous/meta-synchronous hematolymphoid neoplasms and prostatic adenocarcinoma. Our data provides one of the largest institutional series in this regard. Additional data and follow up is needed to evaluate if the concurrent low grade hematolymphoid malignancy, specifically small lymphocytic lymphoma/chronic lymphocytic leukemia, affects the survival outcome in these patients.